Approval · Notice of Compliance 23744 · 2020
ALEVE TABLETS: Notice of Compliance 23744
Issued June 5, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23744
- Date
- June 5, 2020
- Company
- Bayer Inc.Elkhart, Indiana, United States
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Brand name change, Labelling updates to comply with the Plain Language Labelling requirements
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALEVE TABLETS | 02301733 | Marketed |
Medicinal ingredients
- NAPROXEN SODIUM 220 MG per TAB